Merck to Acquire Immune Design: Merck & Co. Inc. (NYSE:MRK) will acquire cancer vaccine company Immune Design Corp. (NASDAQ:IMDZ) to boost its cancer immunotherapy pipeline. Merck will pay $5.85 per share in cash, or about $300 million. The price is a 312% premium to Immune Design\'s closing price of $1.42 Wednesday, before the deal was announced. Immune Design gained $4.40 (310%) to $5.82 on Thursday. Immune Design has two vaccine immunotherapy platforms. Its ZVex lentiviral vectors stimulate dendritic cells to initiate production of antigen-specific cytotoxic immune cells, and its GLAAS platform boosts helper immune cells.
https://www.businesswire.com/news/home/20190221005198/en/
No comments:
Post a Comment